Autopsy report · NCT02222207
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
Cause of deathNo reason given
Life of this trial
- Registered 2 months before it started.
- Ran for about 8 months before it stopped.
- 52 participants enrolled.
- Results were posted on the registry 1 year 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Bayer
- Sponsor type
- Industry
- Conditions
- Macular Degeneration
- Interventions
- Regorafenib, ophthalmic oily suspension (BAY73-4506); Sham IVT; Ranibizumab; Placebo
- Participants
- 52
- Sites
- 149
- Countries
- Australia, Austria, Canada, Chile, Colombia, Czechia, France, Germany, Hong Kong, Hungary, Israel, Italy and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.